The Insight Partners Latest Research on Report “Constipation Treatment Market Forecast to 2027″ Includes COVID-19 Impact and Global Analysis by Therapeutic (Laxatives, Chloride Channel Activators, Peripherally Acting Mu-Opioid Receptor Antagonists, GC-C Agonists, and 5-HT4 Receptor Agonists); Disease (Chronic Idiopathic Constipation, Irritable Bowel Syndrome with Constipation, and Opioid-Induced Constipation); Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies) and Geography
“Constipation Treatment Market is expected to reach US$ 13,386.19 million by 2027 from US$ 8,533.89 million in 2019; it is estimated to grow at CAGR of 5.9% from 2020 to 2027. The report highlights trends prevailing in the market and drivers and hindrances pertaining to the market growth.
Download PDF Sample Copy at:
The irritable bowel syndrome with constipation (IBS-C) is found to be a chronic, recurring, and remitting functional disorder of the gastrointestinal tract that causes abdominal pain, distention, and changes in bowel habits. Irritable bowel syndrome with constipation (IBS-C) is found to affect up to 7%–18% of the population across the world. The constipation treatment market is expected to witness a huge growth due to rising prevalence of chronic constipation and increasing number of FDA approvals and drug development activities are expected to boost the growth of the global constipation treatment market.
Market’s Leading Players:
Market leaders operating in the market have undertaken various organic growth strategies in the constipation treatment market. The constipation treatment market majorly consists of the players such as AbbVie Inc., Takeda Pharmaceutical Company Limited, AstraZeneca, Bausch Health, Sanofi, Bayer AG, Mallinckrodt, Abbott Laboratories Co., Cosmo Pharmaceuticals N.V., Albireo Pharma, Inc. among others. Several in organic approaches, such as mergers & acquisitions and collaboration in the constipation treatment market, have resulted in the positive growth of the market. Mergers & Acquisitions help the company to strengthen its revenue, which allows the company to hold a strong position in the market. Similarly, utilizing expansion activities, it is easy to venture into untapped economies and use the opportunities being offered.
Below is the list of the growth strategies done by the players operating in the constipation treatment market:
Aug-2020: Cosmo Pharmaceuticals to Expand Strategic Partnership with RedHill Biopharma. This strategic partnership aims at extending an exclusive licensing and manufacturing agreement for multiple products including Movantik used in the treatment of opioid induced constipation
Feb-2020: AstraZeneca collaborated with Ironwood Pharmaceuticals, Inc. This collaboration agreement gives AstraZeneca full rights for development, manufacturing and commercialize Linzess (linaclotide) in China. Linzess (linaclotide), a first-in-class new treatment for patients with irritable bowel syndrome with constipation (IBS-C).
Mar-2019: Bausch Health has acquired certain assets of Synergy Pharmaceuticals Inc. for price of approximately $195 million.This acquisition is expected to add Synergy’s flagship products such as TRULANCE (plecanatide), a once-daily tablet approved for adults with chronic idiopathic constipation (CIC) and irritable bowel syndrome with constipation (IBS-C), and its investigational compound, dolcanatide, a peptide with established proof-of-concept studies in multiple GI conditions
Ask for Discount at:
Dec-2017: Mallinckrodt plc, a pharmaceutical company has acquired Sucampo Pharmaceuticals, Inc., a biopharmaceutical company which will add commercial and development assets to the company. This acquisition will gain access to Mallinckrodt to Sucampo’s commercial asset AMITIZA, which is an effective drug for opioid-induced constipation in adult patients
The market is expected to have increased demand for constipation therapies to treat OIC. The increasing incidences of constipation due to the consumption of opioids to treat several chronic diseases are expected to increase. For instance, growing incidences of chronic pain among geriatric people, growing incidences of cancers among people are expected to increase demand for therapies to treat constipation as the treatments given to these health conditions induce constipation. Whereas, unbalanced diet among children, youngsters, adults, and an unhealthy lifestyle is another driving factor for driving the incidence rate for constipation.
On the other hand, the developments in drug development are enhancing opportunities for market growth. The FDA’s approval for μ-opioid receptor antagonists (PAMORAs), naldemedine (opioid receptor antagonist) to treat OIC in adults with chronic noncancerous pain-related syndromes gained attraction in 2017. Since then, a significant rise in the studies to under the effectiveness of PAMORAs to treat OIC. In addition, several studies have shown positive results for naldemedine, and it is estimated to effective and safe first-line therapy for the treatment of OIC among adults with chronic noncancerous pain. Therefore, owing to OIC, the market is expected to grow faster during the forecast period.
Buy Report at:
The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We specialize in industries such as Semiconductor and Electronics, Aerospace and Defense, Automotive and Transportation, Biotechnology, Healthcare IT, Manufacturing and Construction, Medical Device, Technology, Media and Telecommunications, Chemicals and Materials.
If you have any queries about this report or if you would like further information, please contact us:
Contact Person: Sameer Joshi